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iTRAQDiabetic nephropathy, as a severemicrovascular complication of diabeticmellitus, has become the leading cause of
end-stage renal diseases. However, no effective therapeutic strategy has been developed to prevent renal damage
progression to end stage renal disease. Hence, the present study evaluated the protective effects of grape seed
procyanidin B2 (GSPB2) and explored its molecular targets underlying diabetic nephropathy by a comprehensive
quantitative proteomic analysis in db/db mice. Here, we found that oral administration of GSPB2 signiﬁcantly
attenuated the renal dysfunction and pathological changes in db/db mice. Proteome analysis by isobaric tags for
relative and absolute quantiﬁcation (iTRAQ) identiﬁed 53 down-regulated and 60 up-regulated proteins after
treatment with GSPB2 in db/db mice. Western blot analysis conﬁrmed that milk fat globule EGF-8 (MFG-E8)
was signiﬁcantly up-regulated in diabetic kidney. MFG-E8 silencing by transfection of MFG-E8 shRNA improved
renal histological lesions by inhibiting phosphorylation of extracellular signal-regulated kinase1/2 (ERK1⁄2), Akt
and glycogen synthase kinase-3beta (GSK-3β) in kidneys of db/db mice. In contrast, over-expression of MFG-E8
by injection of recombinant MFG-E8 resulted in the opposite effects. GSPB2 treatment signiﬁcantly decreased
protein levels of MFG-E8, phospho-ERK1/2, phospho-Akt, and phospho-GSK-3β in the kidneys of db/db mice.
These ﬁndings yield insights into the pathogenesis of diabetic nephropathy, revealingMFG-E8 as a new therapeutic
target and indicating GSPB2 as a prospective therapy by down-regulation of MFG-E8, along with ERK1/2, Akt and
GSK-3β signaling pathway.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
According to recent estimations, diabetes mellitus (DM) is affecting
about 5–10% of the world population and rising rapidly in younger
population groups, including children and adolescents [1–3]. In the last
decade, diabetic nephropathy (DN), one of the most relevant diabetic
complications, has become the leading cause of end-stage renal disease
(ESRD), with data indicating that type 2 diabetes contributes to a large
proportion of patients under renal dialysis treatment [4]. Although hy-
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rights reserved.underlying mechanism remains unclear [5–7]. Moreover, the current
therapies for DN including intensive insulin treatment, strict lipid
control, reduction of blood hypertension and smoking cessation are
not sufﬁcient to prevent renal deteriorative progression to ERSD [2,8].
Hence, clariﬁcation of the molecular pathogenesis of DN and develop-
ment of novel effective therapeutic strategies are high priorities.
Increasing evidence indicates that hyperglycemia-mediated oxida-
tive stress is an early event and common mediator in the development
of diabetic complications [9–11]. Excessive oxidative stress results
in the activation of major biochemical harmful pathways, including
advanced glycation end-products (AGEs) formation, protein kinase C
(PKC)-extracellular-regulated protein kinase (ERK) pathway, polyol
pathway, and growth factors and cytokines [12,13]. In diabetic rats,
antioxidant treatments with tocotrienol, probucol,α-lipoic acid, taurine,
or resveratrol improved renal complications such as albuminuria and
glomerular hypertrophy by reversing the increased levels of reactive
oxygen species (ROS) and activating antioxidant enzymes [10,14–16].
Therefore, targeting to alleviate oxidative stress may offer new prospec-
tive approaches for DN.
Fig. 1. Effect of GSPB2 on bodyweight in db/dbmice. Values are expressed asmean ± SD.
Asterisk (*) indicating a p b 0.05 versus group CC; pound sign (#) indicating a p b 0.05
versus group DM. CC, control db/m mice; DM, untreated db/db mice; DMT, db/db mice
treated with GSPB2 (30 mg/kg per day for 10 weeks).
Fig. 2. Effect of GSPB2 on the level of FBG(A), AGEs(B), BUN(C), Cr(D) and urinary albumin(
versus group CC; pound sign (#) indicating a p b 0.05 versus group DM.
806 Z. Zhang et al. / Biochimica et Biophysica Acta 1832 (2013) 805–816Grape seed proanthocyanidin extracts (GSPE) is extracted from grape
seeds, possessing a variety of potent pharmacological activities including
anti-oxidative stress, free-radical scavenging, anti-inﬂammation, anti-
AGEs, anti-atherosclerosis and so on [17–19]. Our previous studies have
convincingly demonstrated the protective effects of GSPE on diabetic vas-
cular complications, especially on diabetic kidney [20–22]. Grape seed
procyanidin B2 (GSPB2) is a dimeric form of GSPE, more powerful than
other water-soluble polyphenos in biological activities. GSPB2 has been
reported to possess pharmacologic effects including anti-inﬂammatory,
anti-apoptosis and anti-atherosclerosis [23–25], but little is known
about its effects on DN.
The present study aims to evaluate the renopreventive effects of
GSPB2 and explore its potential target proteins in diabetic nephropathy.
We resorted to mass spectrometry (MS)-based isobaric tags for relative
and absolute quantiﬁcation (iTRAQ) to get comprehensive differentialE) in db/db mice. Values are expressed as mean ± SD. Asterisk (*) indicating a p b 0.05
Fig. 3. Bioinformatic analysis of differentially expressed renal protein after treatment with GSPB2 in db/db mice. GO classiﬁcation of proteins based on (A) cellular component and
(B) molecular functions. (C) Interplaying network of proteins with abundance change generated by Ingenuity pathway analysis (IPA). The red and green nodes represent
up-regulated and down-regulated genes or gene products in db/db mice kidney respectively. The edge represents the biological relationship between two nodes. The intensity
of the node color indicates the abundance and the various shapes of the nodes represent the molecular class of the gene product.
807Z. Zhang et al. / Biochimica et Biophysica Acta 1832 (2013) 805–816protein proﬁles in kidneys of db/db mice. Furthermore, we investigated
the molecular pathway of milk fat globule EGF-8 (MFG-E8), one of the
identiﬁed up-regulated proteins in diabetic kidney identiﬁed by iTRAQ,
through knocking down MFG-E8 and injecting exogenous recombinant
MFG-E8 in db/db mice.
2. Materials and methods
2.1. Materials
The detailed information of the main materials is available in the
Supplemental material.
2.2. Animals
Male C57BLKS/J db/db and their nondiabetic db/m littermates,
(n = 24, 7 weeks old) were purchased from Model Animal Research
Center of Nanjing University (Jiangsu, China). Allmicewere kept at con-
trolled temperature (23 ± 2 °C) and humidity (55 ± 5%) levels under
an artiﬁcial light cycle, with free access to laboratory pellet chow and
tap water. All experimental procedures were approved by the animal
ethics committee of Shandong University. After adaptation for a week,
db/m mice were selected as control group (CC, n = 8). Sixteen db/db
mice were randomly divided into two groups: the vehicle-treated
diabetic group (DM, n = 8) administered normal saline solution and
the other diabetic group (DMT, n = 8) treated with GSPB2 (30 mg/kg
body weight/day) in normal saline solution orally for 10 weeks. Animalswere weighed every week. At the end of the intervention, 24-h urine
samples were collected from mice with metabolic cages to measure
urinary albumin excretion. All mice were then sacriﬁced. Fasting blood
was collected and perfused kidneys were dissected. The sera and tissues
were kept at−80 °C until further analysis.
2.3. Estimation of fasting blood glucose (FBG), AGEs, blood urea nitrogen
(BUN), plasma creatinine concentration (Cr) and urinary albumin
excretion rate
The FBG, BUN, Cr were determined by DVI-1650 Automatic
Biochemistry and Analysis Instrument (Bayer, Germany). AGE spe-
ciﬁc ﬂuorescence determinations were performed by measuring
emission at 440 nm on excitation at 370 nm using a ﬂuorescence
spectrophotometer (HITACHI F-2500, Japan). Urinary albumin levels
weremeasured by a competitive ELISA, according to themanufacturer's
instructions.
2.4. Proteomic analysis
In the experiment, kidneys of four mice per group were analyzed.
Detailed experimental procedures were described in the Supplemen-
tal material. In brief, renal proteins were digested, labeled with iTRAQ
reagents (114 for the peptides of group CC, 117 for group DM, and
115 for group DMT), fractionated with Strong Cation Exchange
(SCX) chromatography and analyzed on mass spectrometers.
Fig. 4. Effect of GSPB2,MFG-E8 RNAi and recombinantMFG-E8 on the protein expression ofMFG-E8 in db/dbmice. A–C, representativeWestern blot picture showing protein expressions
of MFG-E8; D–F, densitometric quantiﬁcation of MFG-E8 by the NIH software ImageJ, values are expressed as mean ± SD. Asterisk (*) indicating a p b 0.05 versus group CC; pound sign
(#) indicating a p b 0.05 versus groupDM. CC, control db/mmice; DM, untreateddb/dbmice; DMT, db/dbmice treatedwith GSPB2 (30 mg/kg per day for 10 weeks); LV–GFP, db/dbmice
transinfectedwith lentiviral vectorwith green ﬂuorescence protein;MRNAi, db/dbmice transinfectedwithMFG-E8 shRNA; reMFG-E8, db/dbmice injected recombinantMFG-E8 through
tail vein at a dosage of 20 μg/kg, twice a week for 4 weeks.
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Ingenuity pathway analysis (IPA) program (http://www.ingenuity.
com)was applied to analyze the pathway of differentially expressed pro-
teins identiﬁed by iTRAQ. The proteins with their ID in IPI database and
corresponding abundance changes were uploaded as an Excel spread-
sheet ﬁle into the Ingenuity software. Each identiﬁer was mapped to its
corresponding gene object in the Ingenuity Pathways Knowledge Base.
Ingenuity software made use of the data to extract interactive networks
between the proteins. A score better than 2 is usually considered as a
valid network.
2.6. Transfection of MFG-E8 shRNA and injection of recombinant MFG-E8
in db/db mice
Lentiviral vectors with short hairpin RNAs (LV–shRNAs) against
MFG-E8 was chosen for silencing MFG-E8 gene expression, and lentiviralvector with green ﬂuorescence protein (LV–GFP) was used as the
MFG-E8RNAi control. BothMFG-E8 LV–shRNAs and LV–GFPwere dilut-
ed to a total volume of 300 μl containing 4 × 107 TU. Male C57BLKS/J
db/db and db/m mice (n = 40, 7 weeks old) were used in this study.
C57BLKS/J db/m mice were selected as control group (CC, n = 8).
Thirty-two db/db mice were randomly divided into four groups: an
untreated diabetic group (DM, n = 8), LV–GFP transinfected db/db
group (LV–GFP, n = 8), MFG-E8 shRNA transinfected db/db group
(MRNAi, n = 8) and recombinant mouse MFG-E8 treated db/db
group (reMFG-E8, n = 8). At the age of 14 weeks, sixteen db/db mice
were transinfected with MFG-E8 shRNAs or LV–GFP by tail vein
injection, respectively. Another 8 db/db mice were injected by 300 μl of
recombinantmouseMFG-E8 prediluted in PBS through tail vein at a dos-
age of 20 μg/kg, twice aweek for 4 weeks. At the end of the intervention,
all mice were fasted overnight and then sacriﬁced. The perfused kidneys
were dissected and kept at−80 °C until further analysis. Western blot-
ting was applied to measure transfection efﬁciency of MFG-E8 shRNAs.
Fig. 5. Light microscopic ﬁndings of renal morphological changes in db/db mice by hematoxylin–eosin (HE) staining at ×400 magniﬁcation. A, control db/m mice; B, untreated
db/db mice; C, db/db mice treated with GSPB2 (30 mg/kg per day for 10 weeks); D, db/db mice transfected with LV–GFP; E, db/db mice transinfected with MFG-E8 shRNA;
F, db/db mice injected with reMFG-E8.
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4% paraformaldehyde-ﬁxed kidneys were embedded in parafﬁn,
sectioned at 5 μm, and stained with hematoxylin–eosin for histological
examination under light microscopy.
For morphometric analysis of the glomeruli, sections were stained
with periodic acid-Sciff (PAS). To quantify the mesangial expansion,
ten glomeruli, randomly selected in the two sections from each mouse,
were evaluated by an investigator unaware of the sections' origins.
Mesangial matrix expansion was determined by the presence of PAS-
positive and nuclei-free area in the mesangium. The glomerular area
was also traced along the outline of the capillary loop using computer-
assisted color image analyzer LUZEX F (Nikon, Tokyo, Japan). Relative
mesangial area was shown as the ratio of mesangial area/glomerular
area.
For ultrastructural evaluation, parts of kidneys were ﬁxed in 3%
glutaraldehyde in cacodylate buffer at 4 °C for 4 h and subsequently
post ﬁxated in a 1% osmium–tetroxide phosphate buffer solution for
1 h. Next, the samples were dehydrated in a graded ethanol series
with acetone, permeated, and embedded in epoxide resin. Ultrathin
sections were stained with uranylacetate and lead citrate, and exam-
ined under an H-800 electron microscope (TEM, Hitachi Electronic
Instruments, Tokyo, Japan).
2.8. Western blot analysis
Proteins from isolated kidneys of db/db mice were separated by
SDS–PAGE and transferred onto polyvinylidene diﬂuoride membranes
(Millipore, Bedford, MA, USA). The transferred membranes were incu-
bated with blocking buffer (1 × PBS and 5% non-fat dry milk) for 1 h
at room temperature and then probed with the primary antibody
(described in Supplemental material) at 4 °C for 24 h. HRP-conjugated
IgG were used as secondary antibodies and detected with enhanced
chemiluminescence (ECL) detection system (Amersham Pharmacia
Biotech, Buckinghamshire, UK). The intensities were quantiﬁed with
the NIH software ImageJ. β-Actin was used as loading control.2.9. Statistical analysis
Statistic analysis was performed with SPSS 16.0 software. All exper-
imental data were represented as mean ± SD and compared by using
ANOVA followed by the post hoc test, least signiﬁcant difference
(LSD). p b 0.05 was accepted as statistically signiﬁcant.
3. Results
3.1. Effect of GSPB2 on body weight, FBG, AGEs, BUN, Cr and urinary
albumin excretion rate
Throughout the experimental periods, the db/db mice exhibited
striking obesity compared with their nondiabetic db/m littermates. As
shown in Fig. 1, body weights were consistently greater in db/db mice
than in db/m mice (p b 0.05). However, the increase of body weight in
db/db mice was signiﬁcantly attenuated from the second week after
GSPB2 treatment (p b 0.05).
The effects of GSPB2 on the FBG, AGEs, BUN, Cr, and 24 h urinary
albumin excretion rate were epitomized in Fig. 2. At the end of experi-
ment, levels of FBG, AGEs, BUN, Cr and urinary albumin excretion
were remarkably elevated in db/db mice as compared to db/m mice.
Treatment with GSPB2 to db/db mice induced a signiﬁcant reduction
in AGEs, BUN, Cr and urinary albumin excretion. However, GSPB2 treat-
ment did not affect blood glucose levels.
3.2. Quantiﬁcation and identiﬁcation of the renal proteome by
iTRAQ analysis
In total, 2842 proteins were identiﬁed to have different abundance
between db/db mice and db/m mice. A strict cutoff value of a 1.5-fold
change resulted in a ﬁnal set of 113 differentially expressed proteins, of
which, ﬁfty-three proteins were down-regulated and sixty proteins
were up-regulated in db/db mice after GSPB2 treatment. Strikingly, a
novel molecule MFG-E8 drew our particular attention, with a 2.23-fold
increase in db/db mice versus db/m mice, and back-regulated by GSPB2
Fig. 6.Morphological and quantitive analysis of mesangial expansion in db/dbmice by periodic acid-Schiff staining (PAS) staining at ×400magniﬁcation. A, control db/mmice; B, untreated
db/db mice; C, db/db mice treated with GSPB2 (30 mg/kg per day for 10 weeks); D, db/db mice transfected with LV–GFP; E, db/db mice transinfected with MFG-E8 shRNA; F, db/db mice
injected with reMFG-E8. a, mesangial area; b, glomerular area; c, relative mesangial area. Values are expressed as mean ± SD. Asterisk (*) indicating a p b 0.05 versus group CC; Pound
sign (#) indicating a p b 0.05 versus group DM.
810 Z. Zhang et al. / Biochimica et Biophysica Acta 1832 (2013) 805–816treatment at a ratio of 0.47. The protein ID in IPI, name, molecular weight
and main functions with abundance changes are epitomized in Supple-
mental Table 1 and Table 2, respectively, Table 1 for down-regulated pro-
teins and Table 2 for up-regulated proteins by GSPB2.
3.3. Bioinformatic functional analysis of differentially expressed renal
proteins after GSPB2 treatment
To gain insights into the biological roles of the differential proteins in
the effect of GSPB2 on diabetic nephropathy, the differentially expressed
proteins were categorized into various location and function classes
based on GO analysis according to UniProt protein knowledge database
and literature search. In the cellular component of GO analysis, the larg-
est proportion of differentially expressed proteinswas located in nucleus
(22%). Proteins located in cytosol (19%) and plasma membranes (14%)
were the next two highest parts. Besides, up to 12% of a total of 113
proteins were located in the mitochondrion (Fig. 3A). The differentially
expressed proteins were clustered into a number of cellular path-
ways. Notably, the majority of changed proteins after treatment with
GSPB2 were associated with protein or amino acid transport and
metabolism, nearly accounting for 19% (Fig. 3B). The proteins involved
in apoptosis/cell cycle/cell differentiation/proliferation and signal trans-
duction constituted of another two prominent functional groups, occu-
pying about 14% and 11%, respectively. Moreover, proteins involved inoxidative stress, carbohydrate and lipid metabolism accounted for 7%,
6%, and 4%, respectively.
Fig. 3C depicts the primary protein network generated by the
ingenuity pathway analysis of the differentially expressed proteins.
This network scored 50 and consisted of 35 proteins involved in apopto-
sis, oxidative stress, andmetabolism. Among these, twenty-two proteins
were present in our iTRAQ list. In particular, MFG-E8, the protein mark-
edly over-expressed in diabetic kidneys, is directly linked to extracellular
signal-regulated kinase 1/2 (ERK1/2) pathway in this network. The
involvement of MFG-E8 in this network indicates that it may play an im-
portant role in the pathogenesis of DN partly through ERK1/2 signaling
pathway.
3.4. Effects of GSPB2, MFG-E8 RNAi and recombinant MFG-E8 on the
protein expression of MFG-E8 in db/db mice
Western blot was carried out to conﬁrm the protein expression of
MFG-E8 detected by iTRAQ and evaluate the transfection efﬁciency of
MFG-E8 RNAi in db/db mice. As shown in Fig. 4A and D, the protein ex-
pression ofMFG-E8was signiﬁcantly increased in db/dbmice compared
to db/m mice, and normalized by GSPB2, corresponding to that of
iTRAQ. Fig. 4B and E indicates MFG-E8 shRNA successfully knocked
downMFG-E8 protein level by ~60% in the kidneys of db/db mice. Con-
versely, the injection of exogenous recombinant MFG-E8 remarkably
811Z. Zhang et al. / Biochimica et Biophysica Acta 1832 (2013) 805–816elevatedMFG-E8 protein expression (p b 0.05) (Fig. 4C and F.). LV–GFP
had no signiﬁcant inﬂuence on the protein level of MFG-E8 (p > 0.05).
Transfection of LV–GFP to db/dbmicewas also conﬁrmed byﬂuorescent
microscopic imaging, shown in Supplemental Fig. 1.
3.5. Effects of GSPB2, MFG-E8 RNAi and recombinant MFG-E8 on the
renal histology of db/db mice
The histological renal alterations of db/db mice subjected to GSPB2,
MFG-E8 RNAi and reMFG-E8 treatment under light microscope are
depicted in Fig. 5. Fig. 5A shows the renal section of db/mmice demon-
strating normal architecturewith normal glomeruli. Fig. 5B portrays the
renal section of the diabetic group exhibiting glomerular hypertrophy,
mesangial expansion related to mesangial cell proliferation and matrix
accumulation, along with visceral epithelial cell proliferation. These
alterations in diabetic kidneys were ameliorated to near normalcy after
treatments with GSPB2, shown in Fig. 5C. LV–GFP transfected db/db
mice showed the similar histological changes as db/db mice (Fig. 5D).
Silencing MFG-E8 signiﬁcantly suppressed glomerular hypertrophy and
mesangial expansion in the kidneys of db/dbmice (Fig. 5E). However, ex-
ogenously added reMFG-E8 to db/dbmice remarkably exacerbated renal
lesions, characterized by notable glomerular hypertrophy, mesangial
expansion and inﬂammatory cell accumulation (Fig. 5F).
3.6. Effects of GSPB2, MFG-E8 RNAi and recombinant MFG-E8 on the
renal mesangial expansion of db/db mice
Mesangial expansion characterized by an increase in PAS-positive
mesangial matrix area was accelerated in the glomeruli of db/db
mice (Fig. 6B), and signiﬁcantly inhibited by treatment with GSPB2
(Fig. 6C). LV–GFP transfected db/dbmice showed the similar mesangial
expansion as db/dbmice (Fig. 6D). MFG-E8 silencing decreasedwhereasFig. 7. Electron microscopic ﬁndings of renal ultrastructural changes in db/db mice, ×15,000
db/db mice transfected with LV–GFP; E, db/db mice transinfected with MFG-E8 shRNA; F, d
trated endothelium; FP, foot processes; Go, Golgi complex; MC, mesangial cell; Mi, mitochoexogenously added reMFG-E8 remarkably increased the PAS-positive
mesangial matrix area in the kidneys of db/db mice (Fig. 6E and F).
Quantitive analysis of mesangial expansion is presented in Fig. 6A–C.
The PAS positive area and total glomerular area in the glomeruli of
db/db mice increased by 116% and 25%, respectively, compared with
that in db/m mice (Fig. 6a and b). Treatment with GSPB2 signiﬁcantly
reduced the extent of mesangial expansion and total glomerular area
in db/db mice, by 40% and 10%, respectively (Fig. 6a and b). MFG-E8 si-
lencing signiﬁcantly decreased whereas exogenously added reMFG-E8
remarkably increased the extent of mesangial expansion and total
glomerular area in db/db mice, shown in Fig. 6a and b. The relative
mesangial area calculated by mesangial area/total glomerular area ratio
increased by 200% in db/db mice as compared with db/m mice. Treat-
ment with GSPB2 and MFG-E8 RNAi signiﬁcantly ameliorated the
increase in the relative mesangial area in db/db mice compared with
that in untreated db/db mice (Fig. 6c).
3.7. Effects of GSPB2, MFG-E8 RNAi and recombinant MFG-E8 on the
glomerular ultrastructure of db/db mice
The ultrastructural changes in kidneys of db/db mice subjected to
GSPB2, MFG-E8 RNAi and reMFG-E8 treatment are shown in Fig. 7A–F.
Fig. 7A represents the renal ultrastructure of db/m mice showing
the normal glomerular basement membranes (GBMs), podocytes and
foot processes. Ultrastructural examination of kidneys of db/db mice re-
vealed irregular thickened GBMswith segmental nail-like prominencies,
deformed podocytes with less Golgi complexes and mitochondria,
extensively fused foot processes and slit pores, presented in Fig. 7B.
Treatment with GSPB2 markedly reversed the ultrastructural changes
of glomeruli in db/db mice (Fig. 7C). The db/db mice transfected by
LV–GFP showed similar ultrastructural changes to those in diabetic
mice (Fig. 7D).The diabetic alterations in kidneys of db/dbmicewere re-
markably attenuated by MFG-E8 silencing (Fig. 7E), but exacerbated by. A, control db/m mice; B, untreated db/db mice; C, db/db mice treated with GSPB2; D,
b/db mice injected with reMFG-E8. BM, basement membrane; Cap, capillary; FE, fenes-
ndria; PC, podocytes.
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light microscope.
3.8. Effects of GSPB2 and MFG-E8 on the phosphorylation of ERK1/2 in
db/db mice
The phosphorylation level of ERK1/2 was remarkably higher in
the kidneys of db/db mice than in db/m mice, and was signiﬁcantly
suppressed by treatment with GSPB2, (Fig. 8A). MFG-E8 silencing signif-
icantly decreased the phosphorylation level of ERK1/2 by 60% compared
with db/db mice (Fig. 8B). Conversely, exogenous MFG-E8 resulted in a
signiﬁcantly increased level of phospho-ERK1/2 in kidneys of db/db
mice (Fig. 8C), while total ERK1/2 protein level had no signiﬁcant
differences among these groups. These results suggested that MFG-E8
activated phosphorylation of ERK1/2, and GSPB2 down-regulated the
activation of ERK1/2 in diabetic kidney.
3.9. Effects of GSPB2 and MFG-E8 on the phosphorylation of Akt in
db/db mice
The phosphorylation level of Akt was remarkably increased in the
kidneys of db/dbmice than in db/mmice. GSPB2 treatment signiﬁcantly
suppressed the phosphorylation of Akt (Fig. 9A). MFG-E8 silencing sig-
niﬁcantly decreased whereas exogenous MFG-E8 remarkably increasedFig. 8. Effect of GSPB2 and MFG-E8 on the phosphorylation level of ERK1/2. A–C, represe
densitometric quantiﬁcation of p-ERK1/2 and total ERK1/2 by the NIH software ImageJ, value
sign (#) indicating a p b 0.05 versus group DM.the phosphorylation level of Akt, without signiﬁcant differences on the
level of total Akt (Fig. 9B and C). These results indicated that MFG-E8
activated phosphorylation of Akt, and GSPB2 suppressed phosphoryla-
tion of Akt in diabetic kidney.
3.10. Effects of GSPB2 and MFG-E8 on the phosphorylation of GSK-3β in
db/db mice
The phosphorylation of GSK-3βwas notably increased in db/db mice
compared to db/m mice, and was signiﬁcantly suppressed by treatment
with GSPB2, as shown in Fig. 10A. Silencing theMFG-E8 gene remarkably
decreased the level of phospho-GSK-3β, approximately by 50% (Fig. 10B).
Oppositely, exogenous MFG-E8 remarkably increased the level of
phospho-GSK-3β in db/db mice (Fig. 10C), while total GSK-3β protein
level had no signiﬁcant differences among these groups. These results
suggested that MFG-E8 triggered the phosphorylation of GSK-3β, while
GSPB2down-regulated the phosphorylation ofGSK-3β in diabetic kidney.
4. Discussion
DN is one of the major microvascular complications and accounts
for a large proportion of patients under renal dialysis treatment.
However, the current therapies for DN are limited to intensive insulin
treatment, strict lipid control, reduction of blood hypertension andntative Western blot picture showing expressions of p-ERK1/2 and total ERK1/2; D–F,
s are expressed as mean ± SD. Asterisk (*) indicating a p b 0.05 versus group CC; pound
Fig. 9. Effect of GSPB2 and MFG-E8 on the phosphorylation level of Akt. A–C, representative Western blot picture showing expressions of p-Akt and total Akt; D–F, densitometric
quantiﬁcation of p-Akt and total Akt by the NIH software ImageJ, values are expressed as mean ± SD. Asterisk (*) indicating a p b 0.05 versus group CC; pound sign (#) indicating a
p b 0.05 versus group DM.
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but not sufﬁcient to prevent renal deteriorative progression to ERSD
[2,8]. As numerous evidences have pointed to the role of oxidative
stress in the development of DN [9–11], we investigated the effects
of GSPB2, a natural antioxidant, on kidneys of db/db mice.
Our present results showed long-term oral treatment with GSPB2
signiﬁcantly blocked the gain of body weight in db/db mice (Fig. 1),
suggesting an anti-obesity effect of GSPB2 on type 2 diabetes. GSPB2
also prevented the increase in AGE level in db/db mice, suggesting an
anti-non-enzymatic glycation effect of GSPB2. GSPB2 treatment in db/db
mice normalized the deteriorated renal function indicated by increased
serum levels of BUN, Cr, and 24 h urinary albumin (Fig. 2C, D, E). Both
mesangial expansion characterized by PAS-positive area and GBM thick-
ening were signiﬁcantly suppressed by GSPB2 treatment in glomeruli of
db/db mice (Figs. 5, 6, 7). GSPB2 reduced the glucose level of db/db
mice, but not signiﬁcantly, suggesting its renoprotective effects indepen-
dent of anti-hyperglycemia.
Diabetic nephropathy is hallmarked by the onset of albuminuria and
abnormal glomerular ﬁltration barrier, i.e., thickened GBMs, glomerular
hypertrophy,mesangial expansion, and loss of podocytes [26].Mesangialexpansion is regarded as one of the most striking characteristics of
DN and strongly associated with ESRD in human diabetics [27–29]. The
db/db mice, a rodent model for type 2 diabetes, could develop the path-
ophysiological alterations and deteriorated renal functions closely simi-
lar to that of human diabetic nephropathy [30,31]. In the current study,
the elevated levels of BUNandCr, increased albuminuria, andexacerbated
glomerular histological alterations in db/db mice indicated the develop-
ment of glomerular injury and renal dysfunction. Treatment with GSPB2
abrogated the renal dysfunction and mesangial expansion in db/db
mice, suggesting that GSPB2 effectively reversed diabetic renal injury
and prevented renal deteriorative progression to ERSD.
In diabetic kidney, accumulation of AGEs results in structural
and functional alterations of some critical enzymes and proteins in
mesangium and glomerular basement membranes [32]. Notably, AGEs
binding to speciﬁc receptors (RAGEs) on podocytes, mesangial and
tubular epithelial cells can activate intracellular signaling pathways
leading to diverse consequences, including the generation of reactive
oxygen species (ROS), activation of transcription factors and release of
inﬂammatory cytokines [32–34]. In our present study, treatment with
GSPB2 for 10 weeks signiﬁcantly decreased the serum AGEs in db/db
Fig. 10. Effect of GSPB2 andMFG-E8 on the phosphorylation level of GSK-3β. A–C, representativeWestern blot picture showing expressions of p-GSK-3β and total GSK-3β; D–F, densitometric
quantiﬁcation of p-GSK-3β and total GSK-3β by the NIH software ImageJ, values are expressed as mean ± SD. Asterisk (*) indicating a p b 0.05 versus group CC; pound sign (#) indicating a
p b 0.05 versus group DM.
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decreasing serum level of AGEs and renal protein expression of RAGE
[21]. In this context, we deduced GSPB2 elicited its renoprotective
effects partly due to the decrease of serum AGE level.
ERK1/2 is a member of the mitogen-activated protein kinases
(MAPKs) family, which responds to various extracellular stimuli such
as ROS, modulating cell growth, proliferation, apoptosis and essential
biosynthetic functions [35]. Activation of ERK1/2 was involved in in-
ﬂammation and oxidative stress, leading to mesangial expansion in
diabetic nephropathy [36–40]. In our present study, GSPB2 treatment
inhibited the phosphorylation of ERK1/2 in kidneys of db/db mice
(Fig. 8A). The phosphoinositide 3-kinase (PI3K)/Akt pathway is a cen-
tral signaling cascade whose activation leads to cellular proliferation,
anti-apoptotic responses, enhanced metabolism, and inﬂammatory
response [41]. Activation of Akt has been reported to play a pivotal
role in the mesangial cell survival, oxidant stress, tubular hypertrophy
and mesangial expansion [42–44]. In our study, activation of Akt in
kidneys of db/db mice was inhibited by GSPB2 treatment (Fig. 9A).
We also found that phosphorylation of GSK-3β in kidneys of db/db
mice was suppressed by GSPB2 treatment (Fig. 10A). GSK-3β, as a
downstream molecule of ERK1/2 and Akt, is a constitutively active
serine/threonine kinase inactivated via phosphorylation on the resi-
due serine-9, accounting for a variety of biological events, includingembryonic development, cell differentiation, apoptosis, and insulin
response [45]. In cultured renal mesangial cell, phosphorylation of
GSK-3βmediates IGF-1-inducedmesangial cell-cycle progression, hyper-
trophy and extracellular matrix protein synthesis [46]. In our current
study, GSPB2 treatment inhibited the phosphorylation of GSK-3β, along
with EKR1/2 and Akt (Fig. 8A, 9A, 10A) in kidneys of db/db mice.
Hence, we deduced that GSPB2 attenuated diabetic renal injury by regu-
lation of EKR1/2, Akt and GSK-3β signaling pathway.
iTRAQ analysis identiﬁed ﬁfty-three down-regulated and sixty
up-regulated proteins after GSPB2 treatment in kidneys of db/db mice.
The targeting proteins with differential abundance (Supplemental Table
1 and Table 2) played pivotal roles in a number of cellular pathways, in-
cluding material metabolism related to glucose/amino acid/lipid/nucleic
acid metabolism, apoptosis, oxidative stress, cell cycle and proliferation,
signal transduction, and cell adhesion. In our previous study, 2-D dif-
ference gel electrophoresis (2-D DIGE) has revealed that six oxidative
stress proteins were back-regulated by GSPE treatment in kidneys of
STZ-induced diabetic rats [20]. Although the exact mechanism by which
GSPB2 reaches its intracellular targets is unclear, the targeting proteins
of GSPB2 are supposed to participate in the deterioration and restoration
of DN, and provide novel targets for future therapy.
MFG-E8 stood out in our proteomic analysis because it had not pre-
viously been linked directly with diabetic nephropathy, although it has
815Z. Zhang et al. / Biochimica et Biophysica Acta 1832 (2013) 805–816been shown to over-express in aorta of chronic kidney disease (CKD)
rats and STZ-induced diabetic rats [22,47]. MFG-E8 is a membrane-
associated glycoprotein inducing cell-speciﬁc apoptosis and inﬂamma-
tion response [48,49], and plays a diverse biorole in various pathophys-
iologic conditions, including angiogenesis, aging, tissue remodel, and
tumor genesis [50–52]. In patients with CKD, elevated serum MFG-E8
level is positively associated with deteriorated renal function and
increased aortic stiffness [47]. Actually, in our previous study, MFG-E8
has been shown to abundantly express in aorta of STZ-induced diabetic
rats and decrease to normal after GSPE treatment [22], indicating it
may be involved in the pathogenesis of diabetic vascular complications.
Our present iTRAQ analysis (Supplemental Table 1) and Western blot
analysis (Fig. 4A) identiﬁed that MFG-E8 was signiﬁcantly elevated
in diabetic kidneys, and reduced after GSPB2 treatment. Knockdown
of MFG-E8 gene signiﬁcantly suppressed whereas exogenous MFG-E8
exacerbated glomerular hypertrophy, mesangial expansion and thick-
ening basement in db/dbmice (Figs. 5, 6, 7). These results demonstrated
the detrimental role of MFG-E8 in the development of diabetic nephrop-
athy. Our previous vitro study has reported that protein expression
of MFG-E8 was dose-dependently inhibited by GSPB2 treatment in the
apoptotic process of the cultured human umbilical endothelial cells
[24]. We presumed that GSPB2 dose-dependently down-regulated the
protein expression of MFG-E8 by regulating the transcription and
translation of MFG-E8, after binding to speciﬁc receptors located on cell
membranes.
We established the underlying molecular mechanism by which
MFG-E8 accelerates diabetic kidney injury, and uncovered that MFG-E8
acted by activation of ERK1/2, Akt and GSK-3β signaling pathway.
Knocking down the MFG-E8 gene remarkably suppressed whereas
over-expression elevated the phosphorylation of ERK1/2, Akt and
GSK-3β (Figs. 8, 9, 10). ERK1/2 acting as a downstream molecular of
MFG-E8 has been reported to participate in the MFG-E8-induced inva-
sion and proliferation of VSMC in aging aorta [52,53]. Actually, the
links between MFG-E8, ERK1/2 and Akt signaling have been implied
in the protein pathway of IPA (Fig. 3C). Both ERK1/2 and Akt pathway
were activated in diabetic glomeruli mediating collagen I and MCP-1
upregulation in mesangial cells and type 2 diabetic mice [54,55].
GSK-3β is a pivotal convergence point of PI3K/Akt and ERK1/2 [56,57].
Increased phospho-GSK-3β, phosphop-ERK1/2 and phospho-Akt were
found in kidneys of STZ-induced diabetic rats, related with the progres-
sion of DN [58]. In our previous study, GSK-3βwas also found to medi-
ate the apoptosis of endothelial cells induced by MFG-E8 [24]. In the
present study, MFG-E8 silencing inhibited whereas over-expression of
MFG-E8 elevated the phosphorylation of ERK1/2, Akt, and GSK-3β
(Figs. 8, 9, 10). Hence, we deduced thatMFG-E8may aggravate diabetic
renal injury partially by phosphorylation of ERK1/2, Akt and GSK-3β.
Taken together, our research identiﬁedMFG-E8 alongwith activation
of ERK1/2, Akt, and GSK-3β signaling pathway contributed to the patho-
genesis of diabetic nephropathy for the ﬁrst time. GSPB2 performed
potent protective effects on DN by inhibition of MFG-E8, phosphoryla-
tion of ERK1/2, Akt, and GSK-3β signaling pathway, although themolec-
ular mechanism by which GSPB2 down-regulates these molecules in
diabetic kidneys is unclear. Our research provides a new insight into
the pathogenesis of diabetic nephropathy and indicates that targeting
MFG-E8 could be a novel strategy to retard the progression of DN.
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